Case Report: Long-term survival in extensive-stage small cell lung cancer treated with adebrelimab-based combination therapy

The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a detailed case of a 62-ye...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yu Xia, Yuxian Yang, Wanzhong Huang, Yongshun Chen
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-07-01
Serie:	Frontiers in Oncology
Soggetti:	adebrelimab case report chemoimmunotherapy extensive-stage long-term survival PD-L1 inhibitor
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1854258/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!